
Christopher C Patterson, Gisela G Dahlquist, Eva Gyürüs, Anders Green, Gyula Soltész, and the EURODIAB Study Group

Summary

Background The incidence of type 1 diabetes in children younger than 15 years is increasing. Prediction of future incidence of this disease will enable adequate fund allocation for delivery of care to be planned. We aimed to establish 15-year incidence trends for childhood type 1 diabetes in European centres, and thereby predict the future burden of childhood diabetes in Europe.

Methods 20 population-based EURODIAB registers in 17 countries registered 29311 new cases of type 1 diabetes, diagnosed in children before their 15th birthday during a 15-year period, 1989–2003. Age-specific log linear rates of increase were estimated in five geographical regions, and used in conjunction with published incidence rates and population projections to predict numbers of new cases throughout Europe in 2005, 2010, 2015, and 2020.

Findings Ascertainment was better than 90% in most registers. All but two registers showed significant yearly increases in incidence, ranging from 0.6% to 9.3%. The overall annual increase was 3.9% (95% CI 3.6–4.2), and the increases in the age groups 0–4 years, 5–9 years, and 10–14 years were 5.4% (4.8–6.1), 4.3% (3.8–4.8), and 2.9% (2.5–3.3), respectively. The number of new cases in Europe in 2005 is estimated as 15 000, divided between the 0–4 year, 5–9 year, and 10–14 year age-groups in the ratio 24%, 35%, and 41%, respectively. In 2020, the predicted number of new cases is 24 400, with a doubling in numbers in children younger than 5 years and a more even distribution across age-groups than at present (29%, 37%, and 34%, respectively). Prevalence under age 15 years is predicted to rise from 94 000 in 2005, to 160 000 in 2020.

Interpretation If present trends continue, doubling of new cases of type 1 diabetes in European children younger than 5 years is predicted between 2005 and 2020, and prevalent cases younger than 15 years will rise by 70%. Adequate health-care resources to meet these children’s needs should be made available.

Funding European Community Concerted Action Program.

Introduction

Wide variation in incidence of type 1 diabetes in children younger than 15 years has been well characterised by registry reports from the EURODIAB study group within Europe and the DIAMOND project group worldwide. The DIAMOND project also analysed trends by continent in the period 1990–99, and showed increases in every region except Central America and the West Indies. In Europe, where numbers of cases are large enough to enable useful comparisons of rises in incidence in different age-groups, evidence shows that increases in incidence were highest in the youngest age-group. Furthermore, analysis of EURODIAB registration data for 1989–98 in regions within Europe shows that rates of increase differed significantly and were highest in central and eastern European countries.

The emergence of type 2 diabetes in children and adolescents has received much attention, but this issue should not be allowed to overshadow the rapid rises in type 1 diabetes in this age-group. Although in a few countries most cases in children will be type 2 diabetes, in most European countries type 1 diabetes is, and will probably remain, the predominant form of this disease.
Articles

Figure 1: 20 EURODIAB centres in 17 countries split into regions with homogeneous incidence rates
Purple=north region, four centres and 6727 cases. Pink=north west region, three centres and 6673 cases. Orange=west region, five centres and 6198 cases. Green=central region, three centres and 6198 cases. Blue=east region, five centres and 6556.

Statistical analysis

Poisson regression was used to investigate trends in incidence within centres. This method specifies that factors have an additive effect on a logarithmic incidence scale (or equivalently, a multiplicative effect on the incidence scale). For each centre, a base model with terms for age-group (0–4 years, 5–9 years, and 10–14 years), sex, and age-group by sex interaction was fitted. Addition of a linear term for calendar year to this model provided a test for trend with time in the centre that took account of any changes in population age structure during the period, and gave an estimate of the annual percentage rise together with 95% confidence limits. A test for departure from log-linear time trend (ie, a check for deviation from linearity) was obtained by a likelihood-ratio test comparing the linear trend model with a general model that allowed for any pattern of difference between the years. Further models incorporating interaction terms were used to test for differences in linear time trends between sexes and between age-groups within each centre.

Furthermore, Poisson regression was used to compare trends in incidence in the five regions. For this analysis, the base model contained terms for sex, age-group, region, and all possible interactions. This base model, therefore, specified different age and sex-specific incidence rates in each region. Addition of a linear term in calendar year provided a test for time trends that took the form of a single annual percentage rise common to both sexes and all age-groups and regions. Interactions of this term with sex, age, and region tested for different time trends in the sexes, in different age-groups, and regions, respectively. High order interactions between these terms and the linear term in calendar year provided tests for patterns of further complexity (eg, the age by sex by year interaction tested for different patterns of age-specific rises in incidence in boys and girls). Likelihood-ratio $\chi^2$ tests were used to compare fit of nested models with tests undertaken at the 5% significance level. Akaike’s information criterion was also used to aid model selection. A goodness-of-fit test, obtained as a likelihood-ratio test comparing the fit of each model with that of a saturated model that perfectly predicted observed numbers of cases, was used to assess model fit and to

and prescription data. In common with many uses of capture-recapture methods in epidemiology, neither the assumption of source independence nor the assumption of equal probability of capture of each case by any given source is easily verifiable, so our estimates can provide only an imperfect estimate of completeness. Likely to be less sensitive to these assumptions is the comparison of each centre’s completeness estimate during the three 5-year periods, which is especially important when incidence trends are being investigated.

Annual estimates of population in each centre’s geographically defined area were used as denominators for calculation of standardised incidence rates. Standardisation was by the direct method with a standard population consisting of equal numbers of children in each of six subgroups defined by age-group (0–4 years, 5–9 years, and 10–14 years) and sex. To provide appropriate numbers of cases for the estimation of trends in each of these six subgroups, Europe was divided into five regions. Regions were defined by three factors—geography, incidence rate, and numbers of registered cases. The Scandinavian centres (Denmark, Finland, Norway, and Sweden) formed a natural north region of very high incidence, and the three UK centres formed a northwest region of high incidence. An arbitrary target figure of about 5000 registered cases for each centre was chosen. Construction of the three other regions—each of countries with roughly homogeneous incidence rates—was largely guided by results from our previous report, which included data from 44 centres representing most countries of Europe. The west region consisted of Spain, Luxembourg, Belgium, and two German centres; the central region comprised the Czech Republic, Austria, and Slovenia; and the East region consisted of Lithuania, Poland, Slovakia, Hungary, and Romania (figure 1).
check for overdispersion. A significant goodness-of-fit test shows that a model fits the data poorly. All models were fitted by use of Stata 8.

Estimates of new cases in 2005 and predictions for future new cases were made by extrapolation of base-year incidence rates, with the annual percentage increase in incidence in each age-group in the five regions estimated from the Poisson regression analysis. Prevalence figures were derived from cumulated incidence rates. Extrapolated rates were then applied to the EUROSTAT 2005 population estimates and the UN medium variant 2010, 2015, and 2020 population projections. This approach assumes that future annual rates of increase are equal to those derived from the Poisson regression analysis of EURODIAB centre rates in 1989–2003. Base-year incidence rates used for the extrapolation in each country were published rates for the most recently available 5-year period (webappendix p 1). Nationwide estimates were used when available. When the reported rates were based on fewer than 150 cases in the 5-year period, a period of 10 years or 15 years was preferred to obtain more stable rates on which to base extrapolations.

Role of the funding source
The funding source played no part in the study design, collection, analysis, and interpretation of data, writing of the report, or in the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
Table 1 shows the total numbers of cases registered during 1989–2003 in each of the 20 centres and the age-standardised incidence rates in the three 5-year periods. Most centres maintained greater than 90% completeness of ascertainment in all three periods, with many achieving in excess of 95%. For all but two centres, the estimated annual increases in incidence were significant. Use of a log linear trend to summarise these data was considered appropriate because the test for departure from linear trend reached significance in only one of the 20 centres. Figure 2 shows an inverse association (Spearman rank correlation, r=−0·52, p=0·02) between the rise in incidence rate during the 15-year period and the average rate during the same period.

Further Poisson regression modelling of interactions provided little evidence of any difference in rates of increase between the sexes, the comparison reaching significance in only one of 20 centres. By contrast, in six centres (Austria, Czech Republic, Finland, Baden Württemberg in Germany, Poland, and Yorkshire in the UK) (table 1) rates of increase differed significantly between age-groups—in every case the lowest rate of increase was recorded in the oldest age-group. Many other centres showed the same pattern though the comparison between age-groups did not attain significance.

The overall annual increase for all centres was estimated as 3-9% (95% CI 3·6–4·2), with corresponding rises in the 0–4 year, 5–9 year, and 10–14 year age ranges of 5·4% (4·8–6·1), 4·3% (3·8–4·8), and 2·9% (2·5–3·3), respectively. To help characterise geographical differences in these patterns, the 20 centres were aggregated into five regions (giving a dataset of 2 sexes×3 age-groups×5 regions×15 years=450 observations). Poisson regression analyses of this dataset are summarised in table 2. First, the base model was fitted (line 1), defining a separate set of six age-specific and sex-specific rates in each region but assuming that these rates did not change in the 15 years. A single log linear term for year, representing a common trend between sexes, age-groups, and regions was highly significant (line 2), but the resultant model failed to provide an adequate fit to the data (goodness-of-fit test p<0·0001). When this trend was allowed to differ between age groups through addition of a term representing an interaction between year and age group (line 3), the likelihood-ratio test for the added term was significant (p<0·0001), indicating different rates of change over time in different age-groups.

Addition of an interaction between year and sex was not significant (line 4), but interaction between year, age, and sex was significant (line 5; p=0·03), which suggests

<table>
<thead>
<tr>
<th>Region</th>
<th>Number of cases</th>
<th>Standardised incidence* per 100 000 (P1; P2; P3)</th>
<th>Completeness of ascertainment (P1; P2; P3)</th>
<th>Increase per year (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria Whole nation</td>
<td>2215</td>
<td>9·0; 9·9; 13·3</td>
<td>99·6%; 100%; 97·6%</td>
<td>4·3% (3·3 to 5·3)</td>
</tr>
<tr>
<td>Belgium Antwerp</td>
<td>318</td>
<td>10·9; 12·9; 15·4</td>
<td>99·2%; 97·9%; 94·8%</td>
<td>3·1% (0·5 to 5·8)</td>
</tr>
<tr>
<td>Czech Republic Whole nation</td>
<td>3479</td>
<td>8·7; 11·7; 17·2</td>
<td>100%; 99·8%; 98·7%</td>
<td>6·7% (5·9 to 7·5)</td>
</tr>
<tr>
<td>Denmark Four counties</td>
<td>657</td>
<td>17·0; 16·3; 22·9</td>
<td>99·8%; 95·5%; 100%</td>
<td>3·2% (1·4 to 5·1)</td>
</tr>
<tr>
<td>Finland Two regions</td>
<td>1306</td>
<td>39·9; 50·5; 52·6</td>
<td>100%; 100%; 100%</td>
<td>2·7% (1·4 to 4·0)</td>
</tr>
<tr>
<td>Germany Baden Württemberg</td>
<td>3362</td>
<td>11·0; 13·0; 15·5</td>
<td>95·6%; 98·3%; 100%</td>
<td>3·7% (2·9 to 4·5)</td>
</tr>
<tr>
<td>Germany Dusseldorf</td>
<td>922</td>
<td>12·5; 15·3; 18·3</td>
<td>92·8%; 97·9%; 95·4%</td>
<td>4·7% (3·1 to 6·3)</td>
</tr>
<tr>
<td>Hungary 18 counties</td>
<td>2152</td>
<td>8·8; 10·5; 11·5</td>
<td>97·9%; 94·9%; 95·5%</td>
<td>2·9% (1·9 to 3·9)</td>
</tr>
<tr>
<td>Lithuania Whole nation</td>
<td>996</td>
<td>7·3; 8·2; 10·3</td>
<td>100%; 100%; 100%</td>
<td>3·8% (2·2 to 5·3)</td>
</tr>
<tr>
<td>Luxembourg Whole nation</td>
<td>148</td>
<td>11·4; 12·3; 15·5</td>
<td>100%; 100%; 100%</td>
<td>2·4% (1·4 to 6·3)</td>
</tr>
<tr>
<td>Norway 8 counties</td>
<td>1380</td>
<td>21·1; 20·5; 24·6</td>
<td>100%; 100%; 100%</td>
<td>1·3% (0·1 to 2·6)</td>
</tr>
<tr>
<td>Poland Katowice</td>
<td>1156</td>
<td>5·2; 7·9; 13·0</td>
<td>95·9%; 99·9%; 99·9%</td>
<td>9·3% (7·8 to 10·8)</td>
</tr>
<tr>
<td>Romania Bucharest</td>
<td>378</td>
<td>4·7; 6·1; 11·3</td>
<td>100%; 100%; 100%</td>
<td>8·4% (5·8 to 11·0)</td>
</tr>
<tr>
<td>Slovakia Whole nation</td>
<td>1874</td>
<td>8·2; 10·3; 13·0</td>
<td>100%; 100%; 100%</td>
<td>5·1% (4·0 to 6·3)</td>
</tr>
<tr>
<td>Slovenia Whole nation</td>
<td>504</td>
<td>7·9; 9·2; 11·1</td>
<td>100%; 100%; 100%</td>
<td>3·6% (1·5 to 5·7)</td>
</tr>
<tr>
<td>Spain Catalonia</td>
<td>1923</td>
<td>12·4; 14·3; 16·0</td>
<td>93·5%; 94·6%; 97·6%</td>
<td>0·6% (−0·4 to 0·6)</td>
</tr>
<tr>
<td>Sweden Stockholm county</td>
<td>1374</td>
<td>25·8; 25·6; 34·6</td>
<td>100%; 100%; 100%</td>
<td>3·3% (2·0 to 4·6)</td>
</tr>
<tr>
<td>UK Northern Ireland</td>
<td>1435</td>
<td>20·0; 24·7; 29·8</td>
<td>98·8%; 99·9%; 99·6%</td>
<td>4·2% (3·0 to 5·5)</td>
</tr>
<tr>
<td>UK Oxford</td>
<td>1615</td>
<td>17·1; 21·7; 22·4</td>
<td>95·3%; 90·2%</td>
<td>2·1% (1·1 to 3·4)</td>
</tr>
<tr>
<td>UK Yorkshire</td>
<td>2117</td>
<td>16·0; 19·7; 23·3</td>
<td>99·3%; 95·5%; 99·7%</td>
<td>3·6% (2·6 to 4·6)</td>
</tr>
</tbody>
</table>

Table 2: Summary of Poisson regression analyses of incidence trends

<table>
<thead>
<tr>
<th>Model</th>
<th>Likelihood ratio test for last term (p value)</th>
<th>AIC</th>
<th>Goodness of fit (p value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Base model*</td>
<td></td>
<td>4095.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>2 Base model+Y</td>
<td>&lt;0.0001</td>
<td>3298.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>3 Base model+Y•Y</td>
<td>&lt;0.0001</td>
<td>3252.9</td>
<td>0.0007</td>
</tr>
<tr>
<td>4 Base model+Y•Y•S</td>
<td>0.53</td>
<td>3255.5</td>
<td>0.0006</td>
</tr>
<tr>
<td>5 Base model+Y•A+Y•S+Y•A•S</td>
<td>0.03</td>
<td>3252.8</td>
<td>0.0020</td>
</tr>
<tr>
<td>6 Base model+Y•Y•A+Y•S+Y•A•S+Y•R</td>
<td>&lt;0.0001</td>
<td>3171.6</td>
<td>0.37</td>
</tr>
<tr>
<td>7 Base model+Y•Y•A+Y•S+Y•A•S+Y•R+Y•R•A+Y•R•S</td>
<td>0.13</td>
<td>3175.0</td>
<td>0.43</td>
</tr>
<tr>
<td>8 Base model+Y•Y•A+Y•S+Y•A•S+Y•R+Y•R•A+Y•R•S+Y•R•A•S</td>
<td>0.79</td>
<td>3181.3</td>
<td>0.39</td>
</tr>
<tr>
<td>9 Base model+Y•Y•A+Y•S+Y•A•S+Y•R+Y•R•A+Y•R•S+Y•R•A•S+Y•R•A•S+Y•R•A•S+Y•R•A•S+Y•R•A•S</td>
<td>0.94</td>
<td>3194.4</td>
<td>0.33</td>
</tr>
</tbody>
</table>

Trends for data from 20 centres grouped into 5 regions. Model 6 is the most parsimonious model providing a reasonable fit, and it also has the smallest AIC value. AIC= Akaike Information Criterion. Model terms are: A= terms for age-groups 0–4, 5–9, and 10–14 years; S= term for sex; R= terms for region (or centre group); Y= term for linear trend across the 15 years; A•S= terms for the interaction between age-group and sex. *Base model+Y+Y•A+Y•S+Y•A•S+Y•R.

Figure 2: Inverse association between rate of incidence increase and average incidence

Incidence rate on horizontal axis, plotted on a logarithmic scale. Spearman rank correlation coefficient $r_s=-0.52; p=0.02$.
Discussion
From review of worldwide epidemiology of childhood type 1 diabetes,1 we noted that Europe provides the most informative data about present incidence trends; European estimates of age-group-specific annual increases have narrower CIs than do estimates from other continents, indicating greater precision. We have extended the analysis of European trends to confirm that the highest rates of increase, at least in relative terms, arise in the youngest age-groups. The most striking changes over time are observed in central and eastern European countries. These increases in countries with lower incidence result in a tendency for incidence rates in Europe to converge.

Although cohort effects have been examined,11–16 results have been equivocal. Incorporation of cohort effects in our model might have improved our ability to predict rates in the future, but a 15-year period is rather short for such an analysis, and the difficulties in separation of period and cohort effects when the predominant pattern of change is one of linear increase are well recognised.17 Notably, incidence of type 1 diabetes in young adults over age 15 years shows little evidence of rising,18,19 but a higher incidence in men than in women is widely reported in this age range.20 If type 1 diabetes really is shifting toward a younger age at diagnosis, lower incidence rates in women 15 years or older might help to explain the low rates of increase in girls in the 10–14 year age range seen in all five regions.

Our extrapolation of rates to predict numbers of new cases in future years assumes that log linear trends fitted to age-specific incidence rates in the EURODIAB register data for 1989–2003 will continue into the future. Although we found no evidence of systematic departures from log linear trends, either in our centre-by-centre analysis or

Figure 3: Incidence rate increases by region
Points=observed annual rate. Lines=trends in rates predicted by the best fitting Poisson regression model.
analysis of the five regions, this absence of evidence does not provide any guarantee that our assumption will be valid; moreover, brief periods of apparent stabilisation of rates have been reported.22,23 However, such periods appear to be transient, and the general trend in incidence continues to be upward in the long term. We have examined the likely consequences for incidence of type 1 diabetes in Europe if our assumption of a log linear increase holds, and we predict numbers of new cases in children younger than 5 years old will double between 2005 and 2020. Regional differences in European incidence rates might become less pronounced, because low-incidence countries in eastern and central Europe have the most rapid rises in rates.

Our analysis gives no explanation for the time trends we have described, but the rapid changes over time clearly cannot be attributable to changes in prevalence of susceptibility genes. One suggestion is that need for genetic susceptibility has lessened over time because of heightened environmental pressure, which results in a raised disease progression rate—especially in individuals with protective HLA genotypes.23 Several hypotheses based on analytical epidemiological studies have pointed to modern lifestyle habits as possible environmental factors, such as increased weight and height development,27 and caesarean section deliveries,28 or reduced frequency of early infections.29 This notion accords with reported ecological associations between estimates of gross domestic product and incidence rate in European countries.30 Faster rates of increase in countries with low incidence rate—in particular eastern European countries—might be an expression of effects of lifestyle factors, which are changing rapidly in these countries; therefore, convergence of incidence rates might reflect harmonisation of lifestyle-related risk factors in Europe.

The predicted rise in childhood type 1 diabetes in Europe during the next 20 years, and the raised proportion of cases diagnosed at younger ages than were before, could result in more cases presenting with ketoacidosis and needing hospital admission. More patients with severe diabetes complications presenting at younger ages than before are also likely, and appropriate care from diagnosis, and maintenance of good metabolic control are crucial for delay or prevention of these adverse complications.31 In the absence of any effective means to prevent type 1 diabetes, European countries need to ensure appropriate planning of services and that resources are in place to provide high-quality care for the increased numbers of children who will be diagnosed with diabetes in future years.

**EURODIAB study group**

Austria E Schober (Department of Paediatrics, Medical University of Vienna, Vienna), T Waldhoer (Department of Epidemiology, Medical University of Vienna, Vienna), Belgium I Weets, R Roosman, F Gorus (Belgian Diabetes Registry, Brussels). Czech Republic—O Cínek, Z Sumnik (University Hospital Motol, Second Medical School, Charles University, Prague). Denmark J Svensson, H Mortensen (Paediatric Department, Glostrup Hospital, Glostrup). Finland V Harjutsalo, I Sjöberg, J Tuomilehto (National Institute for Health and Welfare, Helsinki). Düsseldorf, Germany J Rosenbauer, G Giani (German Diabetes Centre, Leibniz Center at Düsseldorf University, Düsseldorf). Baden Württemberg, Germany A Neu, S Ehehalt (University Children’s Hospital, Tuebingen). Hungary O Soltész, E Gyorits (Department of Paediatrics, Pécs University, Pécs). Lithuania B Urbanaitė, R Zalinekvičius, D Mączyński (Institute of Endocrinology, Kaunas University of Medicine, Kaunas). Luxembourg C de Beaufort, U Schierloh (Paediatric Clinic of Luxembourg). Norway G Joner, T Skrivarhaug (Ullevål University Hospital, Oslo). Poland P Jaracz-Chobot, G Deja (Department of Pediatrics, Endocrinology and Diabetes, Medical University of Silesia).
Katowice), J Polanska (Institute of Automatic Control, Silesian University of Technology, Gliwice), Romania C Ionescu-Tirgoviste, N Pauelscu (Institute of Diabetes and Metabolic Diseases, Bucharest), Slovakia I Barak (First Paediatric Clinic, University of Komensky, Bratislava), Slovenia C Kriznik, T Battelino, N Bratina (Department of Endocrinology, Diabetes and Metabolic Diseases, University Children’s Hospital, Ljubljana), Spain C Castell, N de Lara (Public Health Division, Department of Health, Barcelona), A Goday (Hospital del Mar, Barcelona), Sweden G Dahlquist, I Mustonen (Department of Clinical Sciences Paediatrics and Department of Epidemiology, Umeå University, Umeå), Northern Ireland, UK C Patterson, C Cardwell, D Carson (Epidemiology Research Group, Queen’s University Belfast, Belfast), Oxford, UK I Wilson, E Gale, P Bingley (Department of Clinical Science at North Bristol, University of Bristol, Bristol), Yorkshire, UK—P McKinney, J Bodansky, R Felthower (Paediatric Epidemiology Group, University of Leeds, Leeds).

Conflicts of interest
We declare that we have no conflicts of interest.

Acknowledgments
We thank Gerda Brutti, who was administrator for the EURODIAB study group during its first decade, the Austrian Diabetes Incidence Study Group, the Czech Childhood Diabetes Register (supported by Czech Ministry of Education grant MSM 0021660816), the Finnish National Institute for Health and Welfare, the German Paediatric Surveillance Unit, Düsseldorf University and DVP Science Initiative, Ulm University, the Hungarian Childhood Diabetes Epidemiology Group, the Northern Ireland Childhood Diabetes Group, Bart’s-Oxford study group (register funded by Diabetes UK), the Yorkshire Paediatric Diabetes Specialist Interest Group (register funded by the Health Quality Information Partnership, Department of Health, England), and the Swedish Childhood Diabetes Study Group (register funded by the Swedish Research Council, Project number 07531). The collaboration was supported in part by European Community Concerted Action Program grants (MRAP 025/UK, BMHJ-CT92-0043, BMHJ-CT96-0077, and IC20-CT96-0070).

References
23 Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type 1 and type II diabetes. Diabetesologia 2001; 44: 914–22.
26 EURODIAB Substudy 2 Study Group. Rapid early growth is associated with increased risk of childhood Type 1 diabetes in various European populations. Diabetes Care 2002; 25: 1755–60.
The accelerating epidemic of childhood diabetes

Diabetes is one of the most common paediatric chronic diseases. Type 1 diabetes is the leading form of diabetes in young white people, especially those of northern European ancestry. Much of our knowledge of the epidemiology of type 1 diabetes in young people has been generated by large collaborative efforts that were centred on standardised registry data, such as the DIAMOND Project worldwide and the EURODIAB Study in Europe. At the start of the 20th century, childhood type 1 diabetes was rare and rapidly fatal, but by the end of the century a steady increase in incidence had been reported in many parts of the world.

In The Lancet today, Christopher Patterson and the EURODIAB Study Group provide updated estimates of trends in incidence of type 1 diabetes in individuals younger than 15 years in Europe from 1989 to 2003. 15-year incidence data collected by 20 population-based registries in 17 countries were used to estimate rates of increase in geographical regions in Europe. Model-based rates of increase were then used to predict the number of new cases throughout Europe by 2020. The prediction is that between 2005 and 2020, new cases of type 1 diabetes in European children younger than 5 years will double and that the prevalence of cases in those younger than 15 years will increase by 70%.

What is the importance of these new data? The observed incidence rates confirm, and in fact exceed, the incidence predicted for 2010 by earlier projections. This finding is the case for both high-risk European countries, such as Finland and Sweden, and lower-risk countries, such as Austria, Lithuania, and Poland. Recent data from the USA, where registry efforts have been less coordinated, suggest similar trends. For example, the multicentre SEARCH for Diabetes in Youth Study recently reported that the 2002–05 incidence of type 1 diabetes in non-Hispanic white people younger than 15 years was 27.5 per 100 000 people per year, a rate that exceeds the incidence predicted for 2010 from older data from Allegheny County. Similarly, the incidence of type 1 diabetes in young people in Colorado in 2002–04 was much higher than that predicted from earlier Colorado data. These findings suggest that the incidence of type 1 diabetes is increasing even faster than before, pointing towards harmful changes in the environment in which contemporary children live.

Collaborative international cohort studies, such as the Environmental Determinants of Type 1 Diabetes in the Young (TEDDY), will hopefully provide conclusive answers about environmental factors that predispose to, or protect from, islet autoimmunity and type 1 diabetes.

Disturbingly, the new EURODIAB data predict a doubling of new cases in children younger than 5 years, due to a faster increase in incidence in this age-group, consistent with previous reports from Europe and the USA. Although the reason for this rapid increase in young children is not clear and urgently requires study, the finding is important for many reasons. First, younger age at onset of type 1 diabetes is typically associated with more acute symptoms at presentation, including an increased risk of diabetic ketoacidosis and admission to hospital. Second, the changing disease patterns mean that young people with diabetes will have a longer duration of exposure to an altered metabolic milieu, which substantially increases the risk of chronic microvascular and macrovascular complications. However, large-scale clinical trials and translational and epidemiological research in young people with diabetes are scarce, and hampered by the lack of common standardised protocols and validated surrogate endpoints that can be compared across studies. Third, the economic cost of diabetes is already high; increases in the number of people with type 1 diabetes, coupled with the need for high-quality
disease management, will have a devastating effect on health-care costs.

What do these projections mean for the rest of the world? Epidemiological data for type 1 diabetes are still lacking for most of the global population of children, especially in Africa, Asia, and South America. However, recent projections suggest that the prevalence of type 1 diabetes in young people will increase most in less developed parts of the world, even though the incidence is now lowest there. Even in the USA, there are only limited recent data for incidence and trends in childhood type 1 diabetes. Moreover, type 2 diabetes now presents at younger ages and is becoming the major form of diabetes in young people in several non-white populations, such as Native Americans, Asian and Pacific Islanders, and African-Americans. Evidence also suggests an increased risk of diabetes-related chronic complications in young people with type 2 diabetes compared with those with type 1 diabetes. With the exception of SEARCH, no comprehensive population-based studies of diabetes according to type in young people of diverse racial or ethnic backgrounds exist. It is imperative that efforts directed at surveillance of diabetes in young people continue and expand, not only to understand its complex aetiology, but also because of its increasing public health importance.

Dana Dabelea
Department of Epidemiology, Colorado School of Public Health, University of Colorado, Denver, CO 80045, USA
Dana.Dabelea@ucdenver.edu

I declare that I have no conflicts of interest.